Jacques J. Gorlin has been a consulting economist since October, 1982. He is a recognized expert on the nexus between intellectual property and trade policy and has been a consultant to the research-based pharmaceutical industry for twenty years.

Mr. Gorlin served as the Director of the Intellectual Property Committee, an ad-hoc coalition of major U.S. corporations whose expertise both on the substance and politics of international intellectual property protection is today widely recognized. Mr. Gorlin is Vice-Chair of the Industry Trade Advisory Committee on Intellectual Property Rights (ITAC 15), a private sector group that advises the Secretary of Commerce and the U.S. Trade Representative on trade policy, and is a member of the Commission on Intellectual Property of the International Chamber of Commerce.

He was an industry advisor to the US Delegations to both the 2003 (Fifth) and 2005 (Sixth) Ministerial Conferences of the World Trade Organization held, respectively, in Cancun, Mexico and Hong Kong, SAR.  Mr. Gorlin served as an official industry observer at the Fourth meeting of the CBD Ad-Hoc Open-Ended Working Group on Access and Benefit Sharing held in Granada, Spain in February, 2006 and chaired the intellectual property panels at the 34^th and 35^th sessions of the World Congress of the International Chamber of Commerce in 2002 and 2004.  Mr. Gorlin served as a member of the U.S. Delegation to the APEC Seminar on TRIPS Implementation in Sydney, Australia.

He also serves as the President of the American BioIndustry Alliance (ABIA), which was established in September 2005 by American biotechnology companies to provide focused advocacy in support of the full patentability of biotechnology inventions and the maintenance of the current minimum international standards for the protection of intellectual property needed to sustain and encourage biotechnology research and development.

As a member of IFAC 3, the predecessor industry advisory group to ITAC 15, Mr. Gorlin closely monitored the 1992 Rio negotiations that established the Convention of Biological Diversity (CBD) and provided industry views to U.S. negotiators on the intellectual property-related provisions of that treaty. Since, he has provided ongoing advice to the pharmaceutical industry on CBD-related issues, including an analysis of the implications for the pharmaceutical industry of U.S. membership in the CBD.

Mr. Gorlin received an A.B. in history from Columbia College (1965), an M.A. from the Johns Hopkins School of Advanced International Studies (1967) and his Ph.D. from the Johns Hopkins University (1971).